STEPHEN DAVIS - 29 Apr 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: CEO, Director
Signature: /s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 29 Apr 2023
Net transactions value: -$165,331
Form type: 4
Filing time: 02 May 2023, 19:02:53 UTC
Previous filing: 07 Apr 2023
Next filing: 03 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise	$0	+15,625	+16%	$0.000000	116,103	29 Apr 2023	Direct
transaction	ACAD	Common Stock	Sale	$165,331	-7,806	-6.7%	$21.18	108,297	01 May 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-15,625	-100%	$0.000000^*	0	29 Apr 2023	Common Stock	15,625		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	The restricted stock units vest in four equal annual installments beginning April 29, 2020.